抗肥胖药物市场概览、增长、趋势、分析、研究报告(2025-2031)

  • Report Code : TIPRE00006850
  • Category : Life Sciences
  • Status : Published
  • No. of Pages : 310
立即购买

预计到2031年,减肥药物市场规模将从2024年的158.5亿美元增至1772.7亿美元。预计2025年至2031年期间,该市场的复合年增长率将达到35.3%。精准医疗和个性化减肥药物治疗方案可能会在预测期内带来新的市场趋势。

 

减肥药市场分析

根据世界卫生组织(WHO)的数据,1990年至2022年间,全球肥胖患病率增长了一倍以上。2022年,18岁及以上成年人超重人数将达到25亿,其中超过8.9亿人被归类为肥胖:这相当于43%的成年人(男性43%,女性44%),高于1990年的25%。各地区的超重患病率各不相同,WHO东南亚区域和非洲区域的超重患病率最低为31%,而美洲区域的超重患病率则高达67%。降低肥胖率可以减轻与肥胖相关的经济负担。根据世界肥胖地图集,与肥胖相关的总成本(包括医疗保健和经济生产力损失)预计到 2035 年将超过 4 万亿美元,占全球 GDP 的 3% 左右,而 2020 年这一数字为 1.96 万亿美元。因此,肥胖率的上升以及对糖尿病、心血管疾病和某些类型癌症等相关健康风险的认识,刺激了对抗肥胖药物的需求。

 

抗肥胖药物市场概况

随着肥胖症的日益流行以及人们对体重管理解决方案的认知和需求不断增长,减肥药物市场正在不断扩张。市场上的知名企业正致力于创新和合作,以提升产品的可用性和覆盖范围。然而,副作用和安全问题阻碍了市场的增长。

 

定制此报告以满足您的要求

您可以免费定制任何报告,包括本报告的部分内容、国家级分析、Excel 数据包,以及为初创企业和大学提供优惠和折扣

抗肥胖药物市场:

Anti-obesity Drugs Market
  • 获取此报告的顶级关键市场趋势。
    此免费样品将包括数据分析,从市场趋势到估计和预测。

 

抗肥胖药物市场驱动因素和机遇

 

人们对体重管理解决方案的认识和需求不断提高,推动了市场增长

2013年,美国医学会正式认定肥胖是一种由多种生物因素引发的疾病,需要多种干预措施才能有效治疗和预防。肥胖会增加罹患2型糖尿病、心血管疾病、高血压和某些癌症的风险。公众对这些严重健康风险的认识不断提高,刺激了对体重管理解决方案的需求。这种转变体现在公共卫生倡议和消费者行为的变化中,从而引发了对减肥服务、产品和药品的需求。

各国政府和制药公司正在加大力度,向公众宣传肥胖的危害,尤其是其与糖尿病、心血管疾病和其他慢性疾病的关联。2024年3月,礼来公司启动了“Get Better”企业品牌宣传活动的下一阶段,重点关注肥胖问题。同年早些时候,礼来公司推出“Get Better”活动,旨在强调其致力于研发和生产有助于人们获得更健康药物的承诺。作为这项持续宣传活动的一部分,礼来公司发布了两部名为《羞耻》和《Big Night》的电影。这两部电影展现了公司对肥胖的看法,强调了肥胖症的严重性以及减肥药物的合理使用。2022年12月,诺和诺德公司发起了“Break the Partnership”活动,旨在教育糖尿病患者、他们的护理人员以及医疗保健专业人员体重对2型糖尿病管理的影响。该活动由前板球运动员卡皮尔·德夫正式发起,旨在鼓励与临床医生讨论针对血糖水平和体重的新治疗方案。在接下来的六个月里,诺和诺德团队通过在各个城市举办宣传活动和科学会议来吸引医疗保健专业人士的关注。

全球范围内,人们对肥胖药物的认知度正在不断提升。根据2025年发表在《美国医学会杂志》(JAMA Network)上的一项横断面研究《肥胖药物使用和公众认知的纵向分析》,2017年7月至2024年2月期间,美国共开出了69,213,936张肥胖管理药物(OMD)处方。2017年7月至2018年6月,处方数量从76万张增至80万张;2023年3月至2024年2月,处方数量从129万张增至151万张,年平均增长率为5.3%。2024年2月,OMD处方数量达到150万张,占所有处方的0.41%。最常用的处方药包括芬特明、司美格鲁肽(Wegovy)、利拉鲁肽(Saxenda)和替泽帕肽(Zepbound)。

 

拓展新兴经济体,创造市场盈利机会

根据 2023 年 7 月发表的《柳叶刀》研究,预计到 2050 年,印度将有约 4.5 亿成年人超重或肥胖。2021 年,全球被归类为超重或肥胖的成年人中有一半以上生活在印度,有 1.8 亿人受到影响;中国有 4.02 亿人;巴西有 8800 万人;俄罗斯有 7100 万人;墨西哥有 5800 万人;印度尼西亚有 5200 万人;埃及有 4100 万人。

根据世界肥胖联合会的数据,越南、印度尼西亚和孟加拉国的肥胖患病率正在上升,近几十年来增长率高达6-9%。由于城市化、久坐不动的生活方式和饮食习惯的变化,新兴国家的肥胖患病率不断上升,这增加了对抗肥胖药物的需求。很大一部分人口仍未得到诊断或治疗,这为制药公司提供了一个尚未完全渗透的市场,使其有机会推出新的疗法并扩大其覆盖范围。礼来公司正准备在2026年之前在印度、巴西和墨西哥推出其减肥和糖尿病药物tirzepatide(糖尿病药物Mounjaro和肥胖药物Zepbound)。

巴西正在加强医疗基础设施和肥胖管理项目,为新型抗肥胖药物的引进和报销营造有利环境。2024年4月,巴西在圣保罗州奥托兰迪亚开设了一家实验室,专门生产糖尿病和肥胖症药物,其中包括Ozempic的活性成分利拉鲁肽。这家由EMS运营的工厂还将生产Ozempic的关键成分索马鲁肽,该成分的专利有效期至2026年3月,目前正接受巴西国家卫生监督局(ANVISA)的审查。该工厂投资6000万巴西雷亚尔(约合1093万美元),是巴西首个此类工厂,将支持联邦政府的“健康经济产业综合体”计划。

根据世界经济论坛的数据,初期获取抗肥胖药物的渠道可能仅限于私人市场和自付费用。不过,未来中等收入国家的保险覆盖和仿制药的出现,或许能够提高这些药物的可及性。因此,不断上升的肥胖率、政府的支持性举措以及产品创新预计将为新兴国家的市场创造未来的增长机会。

 

抗肥胖药物市场报告细分分析

有助于得出抗肥胖药物市场分析的关键部分是类型、药物类别、给药途径、应用和分销渠道。

  • 根据类型,减肥药市场分为处方药和非处方药。2024年,处方药市场占据了更大的份额。
  • 按药物类别,减肥药市场细分为GLP-1激动剂、脂肪酶抑制剂、MC4R激动剂等。GLP-1激动剂在2024年占据了最大的市场份额。GLP-1激动剂细分市场进一步细分为司美格鲁肽、利拉鲁肽和替泽帕肽。
  • 根据应用,减肥药市场可分为抑制食欲、抑制脂肪吸收/消化酶、促进代谢以及联合用药。2024年,抑制食欲类药物占据了最大的市场份额。
  • 就给药途径而言,减肥药市场分为口服和注射两种。2024年,口服药物占据市场主导地位。
  • 根据分销渠道,减肥药市场可分为医院药房、线上渠道和零售药房。2024年,医院药房占据了市场主导地位。

 

抗肥胖药物市场份额地域分析

抗肥胖药物市场报告的地理范围主要集中在五个地区:北美、亚太地区、欧洲、南美和中美、中东和非洲。就收入而言,北美在 2024 年占据全球市场主导地位,预计在预测期内将继续保持主导地位。美国是世界上最大的抗肥胖药物市场。根据国家健康和营养检查调查的数据,2021 年 8 月至 2023 年 8 月,该国成年人肥胖患病率为 40.3%。40-59 岁成年人(46.4%)的肥胖发病率高于 20-39 岁人群(35.5%)和 60 岁及以上人群(38.9%)。肥胖率的激增导致 2 型糖尿病、高血压和心血管疾病等相关合并症增加,导致医疗成本不断上升。因此,对有效的抗肥胖药物以减轻这些健康风险的需求正在上升。

各大制药公司纷纷推出创新疗法,重塑了市场格局。诺和诺德公司基于索马鲁肽的药物Ozempic和Wegovy分别被广泛用于治疗2型糖尿病和肥胖症。根据ClinCalc DrugStats数据库提供的《2013-2022年美国药物使用统计数据》,索马鲁肽在2022年美国最常用的处方药中排名第48位,处方量超过1300万张。这些药物有助于减轻体重,并改善肥胖相关并发症的管理,从而增强了它们在医疗保健提供者和患者中的吸引力。礼来公司也在其GLP-1受体激动剂tirzepatide上取得了进展,分别以Mounjaro和Zepbound的商品名销售,分别用于治疗糖尿病和减肥。 2024 年,礼来公司的股价飙升 16%,此前该公司的新口服减肥药 orforglipron 的 3 期临床试验结果令人鼓舞,表明 40 周内平均体重减轻 16 磅。

 

 

抗肥胖药物市场区域洞察

Insight Partners 的分析师已详尽阐述了预测期内影响抗肥胖药物市场的区域趋势和因素。本节还讨论了北美、欧洲、亚太地区、中东和非洲以及南美和中美洲的抗肥胖药物市场细分和地域分布。

Anti-obesity Drugs Market
  • 获取抗肥胖药物市场的区域具体数据

抗肥胖药物市场报告范围

报告属性细节
2024年的市场规模158.5亿美元
2031年的市场规模1772.7亿美元
全球复合年增长率(2025-2031)35.3%
史料2021-2023
预测期2025-2031
涵盖的领域按类型
  • 处方
  • 场外交易
按药物类别
  • GLP-1激动剂
  • 脂肪酶抑制剂
  • MC4R激动剂
按应用
  • 抑制食欲
  • 抑制脂肪吸收/消化酶
  • 代谢增强
  • 组合
按给药途径
  • 口服
  • 肠外
覆盖地区和国家北美
  • 我们
  • 加拿大
  • 墨西哥
欧洲
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 意大利
  • 欧洲其他地区
亚太
  • 中国
  • 印度
  • 日本
  • 澳大利亚
  • 亚太其他地区
南美洲和中美洲
  • 巴西
  • 阿根廷
  • 南美洲和中美洲其他地区
中东和非洲
  • 南非
  • 沙特阿拉伯
  • 阿联酋
  • 中东和非洲其他地区
市场领导者和主要公司简介
  • 诺和诺德公司
  • 礼来公司
  • 葛兰素史克公司
  • Rhythm制药公司
  • Currax Pharmaceuticals LLC。
  • 维维斯有限责任公司
  • AdvaCare Pharma USA LL
  • 梯瓦制药工业有限公司
  • 太阳制药工业有限公司
  • F.霍夫曼-罗氏有限公司

 

抗肥胖药物市场参与者密度:了解其对业务动态的影响

减肥药市场正在快速增长,这得益于终端用户需求的不断增长,而这些需求的驱动因素包括消费者偏好的转变、技术的进步以及对产品益处的认知度的提升。随着需求的增长,企业正在拓展产品线,不断创新以满足消费者需求,并抓住新兴趋势,从而进一步推动市场增长。

市场参与者密度是指特定市场或行业内企业或公司的分布情况。它表明特定市场空间内竞争对手(市场参与者)的数量相对于其规模或总市值而言。

在抗肥胖药物市场运营的主要公司有:

  1. 诺和诺德公司
  2. 礼来公司
  3. 葛兰素史克公司
  4. Rhythm制药公司
  5. Currax Pharmaceuticals LLC。
  6. 维维斯有限责任公司

免责声明以上列出的公司没有按照任何特定顺序排列。


Anti-obesity Drugs Market

 

  • 了解抗肥胖药物市场的主要参与者概况

 

抗肥胖药物市场新闻和最新发展

抗肥胖药物市场评估是通过收集一手资料和二手资料后进行的定性和定量数据进行的,这些数据包括重要的企业出版物、协会数据和数据库。以下是抗肥胖药物市场的主要发展:

  • 丹麦制药商诺和诺德公司(Novo Nordisk)以高达20亿美元的价格收购了总部位于中国的联邦国际公司(United Laboratories International)“3G”减肥候选药物的全球权利。(来源:诺和诺德,2025年3月)
  • 艾伯维 (AbbVie) 与 Gubra A/S(一家专注于代谢和纤维化疾病领域临床前合同研究服务和肽类药物研发的公司)宣布达成许可协议,共同开发用于治疗肥胖症的长效胰淀素类似物 GUB014295。(来源:艾伯维,新闻稿,2025 年 3 月)

 

抗肥胖药物市场报告覆盖范围和交付成果

《抗肥胖药物市场规模和预测(2021-2031)》报告对以下领域进行了详细的市场分析:

  • 抗肥胖药物市场规模以及全球、区域和国家层面涵盖的所有主要细分市场的预测
  • 抗肥胖药物市场趋势以及市场动态,例如驱动因素、限制因素和关键机遇
  • 详细的 PEST 和 SWOT 分析
  • 抗肥胖药物市场分析涵盖主要市场趋势、全球和区域框架、主要参与者、法规和最新市场发展
  • 行业格局和竞争分析,包括市场集中度、热图分析、知名参与者以及抗肥胖药物市场的最新发展
  • 详细的公司简介
  • 历史分析(2 年)、基准年、预测(7 年)及复合年增长率
  • PEST 和 SWOT 分析
  • 市场规模价值/数量 - 全球、区域、国家
  • 行业和竞争格局
  • Excel 数据集
anti-obesity-drugs-market-report-deliverables-img1
anti-obesity-drugs-market-report-deliverables-img2
Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

This text is related
to segments covered.

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

常见问题


What would be the estimated value of the anti-obesity drugs market by 2031?

The market value is expected to reach US$ 177.27 billion by 2031.

What is the expected CAGR of the anti-obesity drugs market?

The market is expected to register a CAGR of 35.3% during 2025–2031.

Which are the leading players operating in the anti-obesity drugs market?

Novo Nordisk AS, Eli Lilly and Co, GSK Plc, Rhythm Pharmaceuticals Inc, Currax Pharmaceuticals LLC., VIVUS LLC, AdvaCare Pharma USA LL, Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries Ltd, and F. Hoffmann-La Roche Ltd are key players operating in the market.

What are the future trends in the anti-obesity drugs market?

Precision medicine and personalized anti-obesity drug regimens are likely to emerge as a new growth trend in the market in the coming years.

What are the factors driving the anti-obesity drugs market growth?

The mounting prevalence of obesity and increased awareness and demand for weight management solutions fuel the market growth.

Which region dominated the anti-obesity drugs market in 2024?

North America dominated the market in 2024.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

The List of Companies - Anti-obesity Drugs Market

  • Novo Nordisk AS
  • Eli Lilly and Co
  • GSK Plc
  • Rhythm Pharmaceuticals Inc
  • Currax Pharmaceuticals LLC.
  • VIVUS LLC
  • AdvaCare Pharma USA LL
  • Teva Pharmaceutical Industries Ltd
  • Sun Pharmaceutical Industries Ltd
  • F. Hoffmann-La Roche Ltd
anti-obesity-drugs-market-cagr

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.